{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Missed dose of any study treatment for all patients: If a dose of any study', 'treatment must be missed, the next dose will be taken as per schedule. All missed and', 'delayed doses should be documented.', 'For doses missed for reasons not related to the protocol/study (eg, a required medical', 'procedure or an unanticipated personal emergency):', 'If a patient missed a full 1 - or 2-week period of study treatment dosing for events that', 'are not related to the protocol or the study the days missed will be replaced. For', 'example, if a patient missed C2D7 to C2D14, then the patient will start the next', 'dosing on C2D7 following the break. Similarly, if a patient misses C3D1 to C3D15,', 'then the patient will start the next dosing on C3D1.', 'The schedule of MM evaluations will be maintained regardless of drug holidays or drug', 'interruptions (Section 11.3.1).', '10.5.2.', 'Vomited Doses of Selinexor', 'If a dose of selinexor is vomited within 1 hour of ingestion, it will be replaced. If vomiting', 'occurs more than 1 hour after dosing, it will be considered a complete dose.', '10.6.', 'Sponsor-supplied Study Treatment Accountability', 'The Investigator or designee must maintain an accurate record of receipt of shipment and', 'dispensing of Sponsor-supplied study treatment in a drug accountability log. Accountability for', 'Sponsor-supplied study treatment will be documented throughout the study and reconciled.', 'Patients will be asked to return all unused Sponsor-supplied study treatment and packaging on a', 'regular basis, at the end of the study or at the time of discontinuation of selinexor. All unused', 'Sponsor-supplied study treatment must be destroyed with accompanied documentation.', '10.7.', 'Compliance', 'The Investigator or other study staff will either directly administer or supervise study treatment', 'given in the clinic and instruct the patient on study treatment self-administration, as appropriate.', 'Patients will be asked to bring their Sponsor-supplied study treatment containers with them at', 'each visit, and compliance with Sponsor-supplied protocol-defined study treatment intake at', 'home will be checked by tablet count.', 'Compliance to oral Sponsor-supplied study treatment taken at home will be assessed by the', 'Investigator and/or study personnel at each visit and recorded in source documents after', 'discussion with the patient and after performing Sponsor-supplied study treatment', 'accountability.', 'The Investigator will account for the number of Sponsor-supplied tablets dispensed against those', 'returned by the patient. Any deviations and missed doses will be recorded in the eCRF and drug', 'accountability logs along with the reasons for subsequent verification.', 'Confidential', 'Page 69', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '10.8.', 'Contraception Requirements and Concomitant Medications', '10.8.1.', 'Contraception Requirements', 'Patients should not become pregnant or father a child while on this study because the study', 'treatments in this study can affect an unborn baby. Women should not breastfeed a baby while', 'on this study. It is important that patients understand the need to use birth control while on this', 'study.', 'Female patients of childbearing potential and fertile male patients must agree to use highly', 'effective contraception listed below (ie, results in a low failure rate when used consistently and', 'correctly) during the dosing period and for a period of at least 3 months after the end of', 'treatment.', 'Highly effective methods include:', 'combined (estrogen and progestogen containing) hormonal contraception associated with', 'inhibition of ovulation:', 'oral', 'intravaginal', 'transdermal', 'progestogen-only hormonal contraception associated with inhibition of ovulation:', 'oral', 'injectable', 'implantable', 'intrauterine device', 'intrauterine hormone-releasing system', 'bilateral tubal occlusion', 'vasectomized partner', 'sexual abstinence', 'Please see Section 4.2.7.1 for additional safety information related to pregnancy.', '10.8.2.', 'Non-study-related Concomitant Medication and Treatment', 'Concomitant medications include any prescription or over-the-counter preparation, including', 'vitamins, dietary supplements, over-the-counter medications, and oral herbal preparations taken', 'during the study. Patients may continue their baseline medication(s) All concomitant', 'medication(s) must be reported in the eCRF. Any diagnostic, therapeutic, or surgical procedure', 'performed during the study period should be recorded, including the dates, description of the', 'procedure(s), and any clinical findings, if applicable.', 'Confidential', 'Page 70', 'Version 4.0']\n\n###\n\n", "completion": "END"}